ATI RN
ATI Pharmacology Practice B Questions
Question 1 of 5
The client takes a bisphosphonate for osteoporosis. Which assessment is best in determining the effectiveness of the medication?
Correct Answer: C
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 2 of 5
A 22-year-old woman is interested in taking oral contraceptives for the prevention of pregnancy. The most likely benefit in terms of disease prevention from oral contraceptives is which of the following?
Correct Answer: B
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 3 of 5
A 53-year-old man with chronic neuropathic back pain and depression is managed with amitriptyline. He has recently complained of urinary frequency and was given a prescription for Ditropan. He now complains of acute abdominal pain and is unable to pass flatus or bowel movement. What is the most likely explanation of this finding?
Correct Answer: C
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 4 of 5
A child is experiencing absence seizures that interrupt his ability to pay attention during school and activities. Which of the following therapies would be most appropriate for this patient?
Correct Answer: A
Rationale: Ethosuximide treats absence seizures by blocking T-type calcium channels in thalamic neurons, reducing 3 Hz spike-and-wave discharges that disrupt attention, ideal for school-aged children. Carbamazepine, a sodium channel blocker, controls focal and tonic-clonic seizures but worsens absence seizures. Diazepam manages acute seizures, not chronic absence. Carbamazepine plus primidone targets other seizure types, not absence. Watchful waiting risks educational impact. Ethosuximide's specificity, efficacy, and pediatric safety make it the most appropriate, per guidelines.
Question 5 of 5
Oral decongestants differ from intranasal decongestants in that oral decongestants
Correct Answer: B
Rationale: Oral decongestants (e.g., pseudoephedrine) act systemically, vasoconstricting vessels beyond the nose, causing effects like hypertension , unlike intranasal decongestants (e.g., oxymetazoline), which are localized but risk rebound congestion. Oral efficacy isn't inherently superior; it's slower. Rebound is nasal-specific. High efficacy is vague. Choice B highlights systemic impact, a key distinction nurses must recognize for safe administration.